Quick Answer
Monte Rosa Therapeutics, Inc. reported Operating Income Loss of -$54.21 million for the year ending 2025.
- Monte Rosa Therapeutics, Inc. showed an increase of +33.2% in Operating Income Loss from 2024 to 2025.
- This data is from Monte Rosa Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 17, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 6 years of available data (2020 to 2025), Monte Rosa Therapeutics, Inc.'s Operating Income Loss has declined by 93.5%.
- Historical annual values: Fiscal year 2025: -$54.21 million | Fiscal year 2024: -$81.11 million | Fiscal year 2023: -$143.31 million | Fiscal year 2022: -$112.38 million | Fiscal year 2021: -$72.88 million | Fiscal year 2020: -$28.01 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: